BridgeBio Pharma (BBIO) net assets (shareholders' equity)

Net assets · fiscal 2025
-$2.09B

BridgeBio Pharma (BBIO) had net assets of -$2.09B at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$1.47B. Figures as of 19 Nov 2026, 01:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
-$2.09B
Highest on record
$408.45Mfiscal 2019
Lowest on record
-$2.09Bfiscal 2025
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

BridgeBio Pharma net assets (shareholders' equity), in more detail

Across the 9 fiscal years on record (2017–2025), the highest was $408.45M in fiscal 2019 and the lowest -$2.09B in fiscal 2025.

History · 9 fiscal years

Net assets by fiscal year

BridgeBio Pharma net assets (shareholders' equity), year by year

BridgeBio Pharma (BBIO) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025-$2.09B—
2024-$1.47B—
2023-$1.35B—
2022-$1.25B—
2021-$870.41M 1,603.1% down
2020$57.91M 85.8% down
2019$408.45M 29.7% up
2018$314.88M 266.8% up
2017$85.85M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of BridgeBio Pharma and comparable companies
CompanyNet assetsFiscal year
ICON ICLR$9.19B2025
Jazz Pharmaceuticals JAZZ$4.32B2025
Solventum SOLV$5.05B2025
BridgeBio Pharma BBIO-$2.09B2025
Summit Therapeutics SMMT$658.86M2025
Glaukos GKOS$656.16M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma net assets (shareholders' equity): questions and answers

What are BridgeBio Pharma's net assets?

BridgeBio Pharma (BBIO) had net assets of -$2.09B at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$1.47B.

What are the highest and lowest net assets figures on record for BridgeBio Pharma?

Across the 9 fiscal years on record (2017–2025), the highest was $408.45M in fiscal 2019 and the lowest -$2.09B in fiscal 2025.

How is BridgeBio Pharma's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For BridgeBio Pharma it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/BBIO/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.